In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The company’s shares closed last Thursday at $4.53.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.6% and a 36.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Revance Therapeutics, and Nektar Therapeutics.
Xeris Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.50.
See today’s analyst top recommended stocks >>
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.79 million and GAAP net loss of $29.18 million. In comparison, last year the company earned revenue of $248K and had a GAAP net loss of $25.28 million.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
